The FDA is requesting that drugmakers remove suicidal ideation and behavior warnings from the labeling of three GLP-1 receptor agonists — Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide) — effective Jan. 13, 2026.
The FDA’s decision follows a meta-analysis of 91 placebo-controlled trials comprising 107,910 patients, according to a Jan. 13 FDA news release. Of those, 60,338 received a GLP-1 receptor agonist and 47,572 received a placebo. The analysis did not identify an increased risk of suicidal thoughts, behaviors or other psychiatric events such as anxiety, depression, irritability or psychosis.
The agency also conducted a retrospective cohort study comparing more than 2.2 million new users of GLP-1 receptor agonists and SGLT2 inhibitors between 2015 and 2023. After adjusting for baseline differences, the FDA found no elevated risk of intentional self-harm among GLP-1 users, including patients with both Type 2 diabetes and obesity.
The warning language was originally included based on earlier concerns and past reports associated with older weight loss drugs. Labeling for GLP-1 receptor agonists approved solely for Type 2 diabetes has not carried the same warnings.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
